Oct 19, 2023 7:00 am EDT Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
Oct 18, 2023 4:30 pm EDT New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
Oct 5, 2023 7:00 am EDT DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
Oct 3, 2023 7:00 am EDT Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
Oct 2, 2023 7:00 am EDT Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
Sep 25, 2023 7:00 am EDT Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Sep 19, 2023 7:00 am EDT Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
Sep 14, 2023 7:00 am EDT TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
Sep 12, 2023 7:00 am EDT Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
Sep 9, 2023 8:00 pm EDT Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
